Exelixis (EXEL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the o ...

Core Insights - Viatris, Inc. (VTRS) announced that its late-stage study on the ophthalmic ointment MR-139 failed to meet primary endpoints in patients with blepharitis, leading to a 4.21% drop in share price [1][6] - Year-to-date, VTRS shares have decreased by 26.8%, contrasting with a 9% decline in the industry [1] Study Details - The MR-139 study was a randomized, placebo-controlled, double-masked phase III trial involving approximately 477 patients, who self-administered the treatment twice daily for 12 weeks [3] - The primary endpoint of complete resolution of eyelid debris after six weeks was not achieved [3][6] Future Plans - VTRS is evaluating next steps for the MR-139 phase III program, which may involve revising the planned additional study [4][6] - The company is focusing on its ophthalmology portfolio, which includes therapies like Tyrvaya and Ryzumvi, and aims to address unmet needs in anterior segment conditions [4] Portfolio Strengthening - VTRS has established an ophthalmology franchise through acquisitions of Oyster Point Pharma and FamyLife Sciences [6] - The company is restructuring its business following the sale of its biosimilar portfolio and divesting its over-the-counter and Active Pharmaceutical Ingredients businesses in India, as well as its women's healthcare segment, to streamline core operations [7]

An updated edition of the June 10, 2025, article.The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025.Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generatio ...

Key Takeaways JNJ beat Q2 estimates and raised full-year guidance on strong pharma performance. Innovative Medicine sales rose despite Stelara LOE, aided by key drugs and new launches. MedTech improvement was led by cardiovascular and surgical products, which offset China-related headwinds.Johnson & Johnson (JNJ) delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara, J&J’s ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

July 18, 2025 02:21 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 7/11) was +4.0% vs. +3.4% last wk and +2.5% over the past 12 wks. For week ended Jul 11, US total market weekly TRx YoY change was +4.0% vs. +1.8% year ago ( Exhibit7 ). Rolling 4-week TRx YoY was +3.0% and rolling 12-week TRx YoY was +2.5%. Extended unit (EUTRx) weekly YoY growth was +3.3%, below TRx YoY ( Exhib ...

策 略 研 究 联系人 王雪蓉 (8621)23297818× wangxr@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 ⚫ 励精图治，开板六年，科创板始终是资本市场深化改革的"试验田"，改革政策一马当先。2019 年 7 月 22 日，首批 25 家科创板企业上市，其审核标准、审核过程及审核内容高度透明，为 A 股市场向 注册制转型树立了首批典范。六年来，多元化上市条件成效显著，截至 2025 年 6 月 12 日，科创板已 有 54 家未盈利企业（上市时）、8 家特殊股权架构企业、7 家红筹企业、20 家通过第五套标准上市企 业以及 1 家转板上市企业。结合科创板最新改革进展，我们认为重点关注三点： 2025 年 07 月 21 日 科创板励精图治，科特估扬帆起航 A 股 策 略 相关研究 - 证券分析师 陆灏川 A0230520080001 luhc@swsresearch.com 王雪蓉 A0230523070003 wangxr@swsresearch.com 牟瑾瑾 A0230524100002 mujj@swsresearch.com 王胜 A02305110 ...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phas ...

Deep application provides foundation for commercial executionPLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities."We are excited to expand our strategic partnership with Veeva ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...